Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Non Operating Income (2017 - 2025)

Moleculin Biotech's Non Operating Income history spans 9 years, with the latest figure at -$50000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$50000.0 for Q4 2025, down 516.67% from a year ago — trailing twelve months through Dec 2025 was -$21000.0 (down 148.84% YoY), and the annual figure for FY2025 was -$20000.0, down 146.51%.
  • Non Operating Income for Q4 2025 was -$50000.0 at Moleculin Biotech, down from $16000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $19000.0 in Q3 2022 to a low of -$50000.0 in Q4 2025.
  • The 5-year median for Non Operating Income is $9500.0 (2021), against an average of $7500.0.
  • The sharpest move saw Non Operating Income skyrocketed 1700.0% in 2023, then crashed 516.67% in 2025.
  • Year by year, Non Operating Income stood at $10000.0 in 2021, then crashed by 90.0% to $1000.0 in 2022, then skyrocketed by 1700.0% to $18000.0 in 2023, then plummeted by 33.33% to $12000.0 in 2024, then crashed by 516.67% to -$50000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$50000.0, $16000.0, and $4000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.